Business Development
Building relationships with industry and academia
Our Business Development division is responsible for managing the work flowing in and out of our Centre for Therapeutics Discovery (CTD).
They are responsible for:
• enabling partnerships where CTD will work on programmes on behalf of industry;
• licensing small molecules and therapeutic antibodies generated by CTD; and
• bringing small molecule and therapeutic antibody targets from academia into the drug discovery pipeline.
News feed
MRCT have recently launched a second collaboration with the University of Bristol in the area of pain medicine.
Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity against Mycobacterium tuberculosis
Researchers at the Breakthrough Breast Cancer Research Unit have used OPT imaging to measure changes in tumour volume.
Barbara Saxty has co-authored a Nature Communications paper entitled An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.